Mike Vallee
Host, ICR Healthcare
Replay available
CVRx, Inc. (NASDAQ: CVRX) Q1 2026 earnings conference call, held 2026-05-11. Replay captured from the company's public earnings webcast.

Host, ICR Healthcare
President and Chief Executive Officer
Chief Financial Officer
Analyst, Canaccord Genuity
Analyst, Lake Street Capital Markets
Analyst, Craig Hallam Capital Group
Greetings and welcome to the CVRX Q1 2026 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Mike Vallee from ICR Healthcare. Thank you. You may begin. Good afternoon. Thank you for joining us today for CBRX's first quarter 2026 earnings conference call. Joining me on today's call are the company's president and chief executive officer, Kevin Hikes, and chief financial officer, Jared O'Shine. The remarks today will contain forward-looking statements, including statements about financial guidance. These statements are based on plans and expectations as of today, which may change over time. In addition, actual results could differ materially due to a number of risks and uncertainties, including those identified in the earnings release issued prior to this call and in the company's SEC filings. I would now like to turn the call over to CBRX's President and Chief Executive Officer, Kevin Hikes. Thanks, Mike. Good afternoon, and thank you for joining our first quarter 2026 earnings call. We delivered a strong start to 2026, exceeding the high end of our guidance range, driven by 22% growth in the United States. The investments we made throughout 2025 are beginning to positively impact our results. Last year, we worked deliberately to strengthen our sales organization, refine our go-to-market approach, advance critical reimbursement initiatives, and to secure approval for our landmark clinical trial. This quarter shows early evidence that the foundation we have built is tra...